CD206-Targeting Peptide Compositions for M2 Macrophage Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack specificity and efficacy in targeting tumor-associated macrophages (M2 TAMs) for therapeutic or diagnostic purposes, as existing peptides and nanobodies do not selectively bind to CD206, leading to non-specific binding to other mannose receptors and limited therapeutic outcomes.
Innovation Solution
Development of conformationally constrained peptides and peptidomimetics, such as CSPGAK, which selectively target CD206-expressing cells, and their use in compositions with detectable agents or therapeutic agents, including polymersomes, to specifically home to MRC1-expressing tumor-associated macrophages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing peptides and nanobodies are used to target tumor-associated macrophages, then they can bind to mannose receptors, but they lack specificity and bind non-specifically to other mannose receptors, resulting in limited therapeutic outcomes
Solution Approach 1:
The patent applies local quality by designing a peptide (CSPGAKVRC) with a specific amino acid sequence that targets only the CD206 mannose receptor subtype expressed on M2 tumor-associated macrophages. The peptide's unique sequence configuration enables it to distinguish and bind specifically to CD206 while avoiding other mannose receptor subtypes, thereby achieving both high binding specificity and reliable therapeutic efficacy in treating solid tumors
2Productivity
If M2 TAMs are targeted for therapeutic intervention, then tumor growth and metastasis can be reduced, but the immunosuppressive microenvironment supported by M2 TAMs must be overcome
Solution Approach 1:
The patent converts the harmful immunosuppressive function of M2 TAMs into a beneficial therapeutic effect by using the CSPGAKVRC peptide to selectively target and deplete these cells. The peptide's specific binding to CD206 on M2 TAMs triggers their elimination, thereby removing the immunosuppressive microenvironment that protects tumors, and simultaneously enhancing the effectiveness of anti-cancer therapies while reducing tumor growth and metastasis
Data Source
Figure 1a~1d
Figure 2a~2h
Figure 3a~3c
AI summary
Described herein are peptides, compositions, and methods for diagnosing, detecting, imaging, monitoring, preventing, treating, or ameliorating diseases or disorders including cancer, inflammatory disorder, and autoimmune disease.